The Indian Council of Medical Research (ICMR) has invited Indian industry partners to collaborate in manufacturing indigenously developed monoclonal antibodies for the treatment of the deadly Nipah virus. This move follows successful animal trials and aims to ensure timely access to the therapy during future outbreaks.
Monoclonal antibodies are lab-engineered proteins designed to replicate the immune system’s natural defense mechanisms against harmful pathogens.
According to ICMR’s Expression of Interest (EoI) document, the Nipah virus (NiV) — known for its exceptionally high fatality rate — continues to pose a major zoonotic threat to India, with recurring outbreaks reported since 2001.
ICMR’s indigenously developed monoclonal antibody therapy for the Nipah virus has shown successful results in animal trials. The council is now seeking industry partners to manufacture the therapy in India, aiming to ensure rapid availability during future outbreaks.